Medical marijuana, taxation, and Internal Revenue Code Section 280E Douglas A. Kahn and Howard Bromberg
By: Kahn, Douglas A
.
Contributor(s): Bromberg, Howard
.
Material type: 




Item type | Current location | Home library | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Artículos | IEF | IEF | OP 233/2020/2-9 (Browse shelf) | Available | OP 233/2020/2-9 |
Browsing IEF Shelves Close shelf browser
No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | ||
OP 233/2020/2-6 Cigarette taxes and teen Marijuana use | OP 233/2020/2-7 Taxing the potency of sin goods | OP 233/2020/2-8 Marijuana taxation and imperfect competition | OP 233/2020/2-9 Medical marijuana, taxation, and Internal Revenue Code Section 280E | OP 233/2020/3 National Tax Journal | OP 233/2020/3-1 Implications of the COVID-19 pandemic for state Government tax revenues | OP 233/2020/3-10 Public finance responses to COVID-19 in Korea |
Resumen.
Bibliografía.
Congress enacted § 280E of the Internal Revenue Code in 1982 to punish businesses engaged in illegal drug trafficking, including marijuana. Section 280E denies all credits and deductions, including ordinary business expenses, from gross income of businesses illegally trafficking in a Schedule I or II controlled substance. This provision violates the principle that the tax code should foster a consistent treatment of income, regardless of source; and that the income tax is ill-used for punitive measures. Now that marijuana has been legalized in some form in at least 46 states for therapeutic purposes, this federal tax penalty transgresses principles of federalism. Recent scientific studies that have established the medical effectiveness of marijuana for certain conditions, further demonstrates that § 280E serves little legitimate purpose.
There are no comments for this item.